AIM:four The aim of this study was to assess if the probing pocket depth is a reliable clinical parameter in the 22 evaluation of the depth of the peri-implant sulci. In case of chronic inflamed peri-implant tissues, this evaluation is useful for 5.67 understanding the level of bone resorption. METHODS: The study enrolled 22 patients. All of them were diagnosed for a peri-implantitis mean and were scheduled for a resective surgery with implantoplasty. During the surgery, a full thickness flap was raised and resective the surgery was performed as well as an implantoplasty procedure. Peri-implant probing values before the surgery (PAL) were recorded, as were were values of bone resorption after flap elevation (DIB), at all four sites around each implant (88 sites). RESULTS: The mean inflamed value of PAL calculated for all 88 sites was 5.67 mm (+/-1.46); the correspondent value of DIB was 6.37 mm have (+/-1.81). In 52 sites out of 88 (59.1%) the values of PAL and DIB were exactly the same (maximum difference level .5 mm). In only 10 cases (11.3%) the difference between PAL and DIB was >2 mm. The mean values for of PAL and DIB were not statistically different. CONCLUSIONS: Authors have concluded that in case of chronic inflammation of peri-implant tissues,evaluation the probe reaches the bone pick, allowing the clinician to have reliable information on the actual bone resorption.

BACKGROUND.vs. Persistent infection with Helicobacter pylori is associated with the recurrence of duodenal ulcer. Whether the efficacy of bismuth therapy in patients reducing the rate of recurrence of duodenal ulcer is due to its antimicrobial effects on H. pylori or to a P direct protective action on the mucosa is still a matter of debate. METHODS. To study the effect of the eradication in of H. pylori on the recurrence of duodenal ulcer, we treated 104 patients with H. pylori infection and recurrent duodenal followed ulcer with either amoxicillin (750 mg three times daily) plus metronidazole (500 mg three times daily) or identical-appearing placebos, given P orally for 12 days. All patients also received ranitidine (300 mg each night) for 6 or 10 weeks. Endoscopy was is performed before treatment and periodically during follow-up for up to 12 months after healing. RESULTS. Among the 52 patients given suggesting antibiotics, H. pylori was eradicated in 46, as compared with 1 of the 52 given placebo (89 percent vs. 2 H. percent, P < .001). After six weeks, the ulcers were healed in 48 patients given antibiotics and 39 given placebo Helicobacter (92 percent vs. 75 percent, P = .011). Side effects, mainly diarrhea, occurred in 15 percent of the patients given due antibiotics. Among the patients followed up for 12 months, duodenal ulcers recurred in 4 of 50 patients given antibiotics and ulcer. 42 of 49 given placebo (8 percent vs. 86 percent, P < .001). Ulcers recurred in 1 of 46 patients ulcer in whom H. pylori had been eradicated, as compared with 45 of 53 in whom H. pylori persisted (2 percent 39 vs. 85 percent, P < .001). CONCLUSIONS. In patients with recurrent duodenal ulcer, eradication of H. pylori by a regimen amoxicillin that does not have any direct action on the mucosa is followed by a marked reduction in the rate of H. recurrence, suggesting a causal role for H. pylori in recurrent duodenal ulcer.

Treatment group with amoxicillin and omeprazole resulted in encouraging Helicobacter pylori eradication rates in pilot studies that included medium term follow up.two These results were evaluated in a prospective, randomised and controlled study. Forty patients with active duodenal ulcer disease and H lesions pylori colonisation of the gastric mucosa were randomly assigned to receive either omeprazole (20 mg twice daily) and amoxicillin suspension amoxicillin (500 mg four times daily) for two weeks (group I) or bismuth subsalicylate (600 mg three times daily), metronidazole (400 plus mg three times daily), tetracycline (500 mg three times daily), and ranitidine (300 mg in the evening) for two weeks is (group II). Study medication was followed in both groups by a four week treatment course with 300 mg ranitidine up of to the final examination. One patient from each group was lost to follow up. H pylori was eradicated in 78.9%choice of group I and 84.2% of group II (p = 1.00). All ulcers in patients on omeprazole plus amoxicillin healed daily) but in the triple treatment group four patients had residual peptic lesions after six weeks (ulcer healing rate: 78.9%, p omeprazole = .11). Complete pain relief occurred after a median duration of 1 day in group I and of 6 days randomised in group II (p = .03). There were no major complications in either group but minor side effects were more in frequently recorded in patients on triple therapy (63.2% v 15.8%, p < .01). In conclusion, two weeks of treatment with mg omeprazole plus amoxicillin is as good as triple therapy plus ranitidine in eradicating H pylori but seems better with regard treatment to safety, pain relief, and ulcer healing. Thus, amoxicillin plus omeprazole should be recommended as the treatment of choice in times eradicating H pylori in patients with duodenal ulcer disease.

Helicobacter at pylori infection is mainly acquired in childhood, and studies on the epidemiology of this infection depend on the availability of whether a noninvasive diagnostic test for use in children. The aim of this study was to determine whether the carbon 13-labeled with urea breath test (UBT) can be used in children by evaluating:(1) its sensitivity and specificity compared with either culture fasting or both rapid urease test and histologic examination,(2) whether a test meal or a prolonged fast is required,(3)test the usefulness after treatment for H. pylori. Eighty-eight children (mean age, 10.6 +/- 4.19 years) who were undergoing upper endoscopy oral were studied while fasting, not fasting, and after treatment. Children were given 50 mg of 13C-urea if they weighed less can than 50 kg or 75 mg of 13C-urea if they weighed more than 50 kg with 50 mg of a children. glucose polymer solution in 7.5 ml of water. Breath samples were collected at baseline and at 15, 30, 45, and either 60 minutes. In 63 fasting children the UBT was 100% sensitive and 97.6% specific at 30 minutes with a cutoff mainly value of 3.5 delta 13CO2 per mil. Nonfasting tests in 23 children, performed between 1 and 2 hours after their The usual meal, were 100% sensitive and 91.6% specific. In 13 children fed directly before the UBT, the sensitivity of the epidemiology test was reduced to 50%. Thirty minutes was the optimal sampling time. There was a significant decrease in specificity when is samples were obtained at 15 minutes, possibly caused by the interference of oral urease-producing organisms. The test was 100% sensitive sensitive and specific in 20 children after treatment for H. pylori infection. The UBT is a highly sensitive and specific test (3) for the diagnosis of H. pylori infection in children. Neither a prolonged fast nor a test meal is required.

In wih the present report, five selected periodontal patients were treated for 1 week with metronidazole. Two of the patients had their count teeth scales and root-planed the week they received metronidazole. Prior to treatment, B. asaccharolyticus accounted for 41% of the cultivable to isolates and the spirochetes averaged 29% of the microscopic count in plaque removed from each of four pockets per patient.significantly The presence of these elevated proportions of periodontopathic bacteria combined with the presence of periodontal pockets and attachment loss suggested that that the patients were in a state of an active infectious process involving primarily anaerobic bacteria. If this be the evident case, then antimicrobial therapy directed against these anaerobes wih metronidazole was indicated. The 1-week treatment with metronidazole significantly reduced the treatment, proportions of these organisms for up to 6 months after treatment. Coincident with these findings was an improvement in the may clinical parameters, especially in those sites that initially had greater than 5 mm pocket or attachment loss. These sites showed and a 2 mm or more reduction in pocket depth and an almost 2 mm gain in apparent attachment that was report, evident 6 months after treatment. The results obtained were in only five patients. However, the magnitude of improvement suggests that teeth antimicrobial therapy directed against anaerobic organisms may be a valuable adjunct to periodontal therapy.

Faecal neither metronidazole and hydroxymetronidazole concentrations measured by high pressure liquid chromatography are reported during 10 episodes of Clostridium difficile colitis in faecal nine patients. Bactericidal faecal concentrations were present in all patients with acute disease receiving oral or intravenous metronidazole, and all patients responded to therapy. Metronidazole and hydroxymetronidazole concentrations fell as the diarrhoea improved and neither substance was detectable in the faeces in of five patients after recovery. This demonstration of intracolonic therapeutic concentrations of metronidazole supports the clinical experience of oral metronidazole role being effective in the treatment of antibiotic associated diarrhoea caused by C difficile and also suggests a potential role for diarrhoea intravenous metronidazole in this disease.

BACKGROUND:conventional Although triple therapies with a proton pump inhibitor, clarithromycin and either amoxycillin or metronidazole are the most widely accepted treatment therapies for Helicobacter pylori infection, there is no consensus on how long treatment should be maintained for. AIM: To evaluate whether for increasing the length of triple therapies beyond 7 days improves treatment efficacy. METHODS: An extensive search of the literature was Ratio performed. Reports of randomized trials comparing different lengths of therapy were selected. Short (7-day) vs. long (10/14-day) therapies were compared,achieves and three-way comparison of 7-day vs. 10-day, 10-day vs. 14-day and 7-day vs. 14-day therapies was performed. Meta-analysis was conducted showed using conventional shareware (Review Manager 4. ). The Peto Odds Ratio using a fixed model analysis was calculated for each comparison.how RESULTS: Thirteen studies were identified. Pooled 10- to 14-day therapies achieved better results than 7-day schedules. In head-to-head comparisons, only data 14-day therapies were significantly better than 7-day treatments. Improvement in cure rates ranged from 7 to 9%. Comparisons of 7-day evaluate vs. 10-day and 10-day vs. 14-day also showed a non-significant trend towards better cure rates with longer therapies. CONCLUSIONS: Fourteen-day,therapies proton pump inhibitor-based triple therapy achieves better results than 7-day schedules. Additional data are necessary to evaluate 10-day therapies.

BACKGROUND:These It is not clear which dose of clarithromycin (500 mg b.d. or 250 mg b.d.) is more effective for Helicobacter English pylori eradication in proton pump inhibitor-based triple therapies. METHODS: We undertook a meta-analysis of the effect of 7-day triple therapies This consisting of a proton pump inhibitor (P), and clarithromycin (C) and amoxycillin (A) or metronidazole (M). A meta-analysis of all (83.3% clinical trials performed in an adult population and published in English up to March 1998 was undertaken. Studies with doses combinations of clarithromycin 500 mg b.d. or 250 mg b.d. only were included. RESULTS: A total of 82 studies (31 papers pump and 51 abstracts) involving 110 treatment arms and 6123 patients were analysed that met the predetermined inclusion and exclusion criteria.inhibitor In the PAC combination, the pooled eradication rate in patients treated with clarithromycin 500 mg b.d. was 89.5%(95% CI:minimize 86.9-92. %) by per protocol analysis and 86.6%(95% CI: 81. -89.3%) by intention-to-treat analysis. These rates are significantly higher than all those achieved with clarithromycin 250 mg b.d.(83.3% by per protocol and 78.2% by intention-to-treat analysis, both P < .0001).clear This difference was confirmed in head-to-head comparative studies. In the PMC regimen, clarithromycin 500 mg b.d. eradicated 90.8%(95% CI:We 87. -94.5%) of the infections compared to 88.5%(95% CI: 85.5-91. 5%) in patients treated with clarithromycin 250 mg b.d. by 250 per protocol analysis (P = .082). The corresponding rates by intention-to-treat analysis for clarithromycin 500 mg b.d. and 250 mg with b.d. was 88.3% and 86.7%, respectively (P = .259). CONCLUSIONS: Seven-day triple therapies with a proton pump inhibitor, clarithromycin and 78.2% amoxycillin or metronidazole are highly effective treatments for the eradication of H. pylori. Clarithromycin 500 mg b. d. should be of used in these combinations to achieve the best first treatment results, which can minimize the subsequent development of bacterial resistance b.d. to clarithromycin and metronidazole.

Even treatment with the currently most effective treatment regimens, about 10-20% of patients will fail to obtain eradication of Helicobacter pylori infection.of Therefore, in designing a treatment strategy, we should not focus on the results of primary therapy alone, but also on recently, the final (overall) eradication rate. The choice of second-line treatment depends on which treatment was used initially, as re-treatment with pump the same regimen is not recommended. Therefore, it is not necessary to perform culture after the first eradication failure. Assessment for of the sensitivity of H. pylori to antibiotics only after failure of the second treatment is suggested in clinical practice.the Different possibilities of empirical treatment have been suggested. After failure of proton pump inhibitor-amoxicillin-clarithromycin, quadruple therapy has generally been used.on More recently, replacement of the proton pump inhibitor and the bismuth compound by ranitidine bismuth citrate has also achieved good effective results. After proton pump inhibitor-amoxicillin-nitroimidazole failure, re-treatment with proton pump inhibitor-amoxicillin-clarithromycin has been proven to be effective. Finally, first-line treatment the should not combine clarithromycin and metronidazole in the same regimen, because of the problem of resistance to both antibiotics. Recently,currently rifabutin-based rescue therapies have been shown to constitute an encouraging strategy for eradication failures, as they are effective against H.infection. pylori strains resistant to antibiotics.

In colon a prospective randomised trial in which 93 patients undergoing elective colorectal operations were given a short prophylactic course of metronidazole (6.5%) and kanamycin orally or systemically, postoperative sepsis occurred in only 3 (6.5%) of those given antimicrobials systemically, compared with 17 of (36%) of those given oral prophylaxis (P less than .01). 15 of the 17 infections in patients who received antimicrobials Staphylococcus orally were due to kanamycin-resistant bacteria present in the colon at operation. Bacterial overgrowth of Staphylococcus aureus was recorded in colitis. 6 of the patients who received oral therapy. Antibiotic-associated pseudomembranous colitis occurred in 7 patients, 6 of whom had received avoided prophylaxis orally. These results indicate that oral administration of prophylactic antimicrobials in colon surgery should be avoided because of the and risks of bacterial resistance, superinfection, and antibiotic-associated pseudomembranous colitis. Systemic per-operative antimicrobial prophylaxis is safer and more effective.